flutamide has been researched along with Adenoma, Prostatic in 41 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors treated 23 benign prostatic hyperplasia (BPH) patients with antiandrogen flutamide." | 9.07 | [The anti-androgen flutamide in the treatment of prostatic hyperplasia]. ( Bach, D; Romics, I, 1992) |
| "To analyze the effects of flutamide in patients with physical and/or mental disorders consulting for urinary symptoms secondary to benign prostatic hyperplasia (BPH)." | 7.70 | [Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery]. ( Granados, EA, 1998) |
| "All flutamide-treated groups had a significant decrease in prostate volume from baseline to the last treatment visit compared to placebo and this reduction was dose related (in comparison to placebo: P < 0." | 6.68 | A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. ( Costello, AJ; Das, S; Debruyne, FM; Jimenez-Cruz, JF; Klimberg, I; Lepor, H; Narayan, P; Schellhammer, PF; Shearer, R; Stone, N; Tewari, A; Trachtenberg, J, 1996) |
| "The authors treated 23 benign prostatic hyperplasia (BPH) patients with antiandrogen flutamide." | 5.07 | [The anti-androgen flutamide in the treatment of prostatic hyperplasia]. ( Bach, D; Romics, I, 1992) |
| "One hundred and seventeen elderly male subjects [60 men without symptoms of prostate hyperplasia, 42 men with untreated benign prostatic hyperplasia (BPH), and 15 men with prostate cancer (PCa)] treated with finasteride or flutamide were included." | 3.78 | Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study. ( Cvijetić, S; Dodig, S; Jurasović, J; Milković-Kraus, S; Mück-Šeler, D; Mustapić, M; Pašalić, D; Pauković, P; Pavlović, M; Pivac, N; Pizent, A, 2012) |
| "To analyze the effects of flutamide in patients with physical and/or mental disorders consulting for urinary symptoms secondary to benign prostatic hyperplasia (BPH)." | 3.70 | [Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery]. ( Granados, EA, 1998) |
| "To investigate the effect of combination endocrine treatment (CET) or luteinising hormone releasing hormone agonist and flutamide on non-neoplastic prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma." | 3.69 | Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. ( Fabris, G; Magi-Galluzzi, C; Montironi, R; Muzzonigro, G; Polito, M; Prete, E, 1994) |
| "All flutamide-treated groups had a significant decrease in prostate volume from baseline to the last treatment visit compared to placebo and this reduction was dose related (in comparison to placebo: P < 0." | 2.68 | A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. ( Costello, AJ; Das, S; Debruyne, FM; Jimenez-Cruz, JF; Klimberg, I; Lepor, H; Narayan, P; Schellhammer, PF; Shearer, R; Stone, N; Tewari, A; Trachtenberg, J, 1996) |
| "For the endocrine therapy of prostate cancer, chlormadinone acetate, flutamide and bicalutamide are or will be available in Japan." | 2.40 | [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications]. ( Akakura, K; Furuya, Y; Ito, H, 1998) |
| "Antiandrogen therapy for benign prostatic hyperplasia (BPH) and prostatic carcinoma has been introduced in clinical practice." | 2.39 | [Application of antiandrogens on prostatic diseases]. ( Hasegawa, F; Isurugi, K; Takahashi, S, 1994) |
| " Pharmacokinetic study with compound 10 at an oral dose of 10." | 1.37 | Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. ( Dalela, D; Gupta, G; Jain, A; Kumar, L; Kumar, R; Lal, J; Lal, N; Maikhuri, JP; Pandey, SK; Prabhakar, YS; Sarswat, A; Sharma, S; Sharma, VL; Verma, V, 2011) |
| "Thirty patients with prostate cancer arising and localizing in the peripheral zone were enrolled in this study." | 1.32 | Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging. ( Nishiyama, T; Takahashi, K; Tomita, Y, 2004) |
| "Their density in prostatic cancer increases following hormonal therapy and varies in relation to the tumoral degree or histological evaluation, suggesting a role of neuroendocrine cells in human prostatic cancer." | 1.30 | Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. ( del Valle, M; Escaf, S; Guate, JL; Menendez, CL; Vega, JA, 1997) |
| " 2) The weight and volume of the mouse prostate diminished in Flu-treated groups, but the dose-response relationship was seen only in volume." | 1.30 | Flutamide suppressed prostate hypertrophy in rats and mice. ( Chen, BL; Li, D; Li, PF; Zhang, YY, 1999) |
| "Flutamide appears to cause hepatotoxic effects in certain patients." | 1.29 | Fatal and nonfatal hepatotoxicity associated with flutamide. ( Freiman, JP; Horton, ML; Tourtelot, JB; Wysowski, DK, 1993) |
| " To determine the specificity of the HF effect, we measured the DHT/HF index in a single prostate at different concentrations of HF in the presence of fixed concentrations of DHT (2 x 10(-8) M) and noted a dose-response relationship." | 1.28 | Measurement of androgen sensitivity in the human prostate in in vitro three-dimensional histoculture. ( Connors, K; Geller, J; Hoffman, RM; Sionit, LR, 1992) |
| " The daily dosage of terazosin was titrated to 5 mg over a 2-week interval." | 1.28 | The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. ( Lepor, H; Machi, G, 1992) |
| "Benign prostatic hypertrophy is a highly prevalent disease, with a significant morbidity." | 1.28 | [Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem]. ( Van Cangh, PJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (26.83) | 18.7374 |
| 1990's | 23 (56.10) | 18.2507 |
| 2000's | 4 (9.76) | 29.6817 |
| 2010's | 3 (7.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarswat, A | 1 |
| Kumar, R | 1 |
| Kumar, L | 1 |
| Lal, N | 1 |
| Sharma, S | 1 |
| Prabhakar, YS | 1 |
| Pandey, SK | 1 |
| Lal, J | 1 |
| Verma, V | 1 |
| Jain, A | 1 |
| Maikhuri, JP | 1 |
| Dalela, D | 1 |
| Gupta, G | 1 |
| Sharma, VL | 1 |
| Oliver, VL | 1 |
| Anderson, C | 1 |
| Ventura, S | 1 |
| Haynes, JM | 1 |
| Pašalić, D | 1 |
| Pauković, P | 1 |
| Cvijetić, S | 1 |
| Pizent, A | 1 |
| Jurasović, J | 1 |
| Milković-Kraus, S | 1 |
| Dodig, S | 1 |
| Mück-Šeler, D | 1 |
| Mustapić, M | 1 |
| Pivac, N | 1 |
| Pavlović, M | 1 |
| Nishiyama, T | 1 |
| Tomita, Y | 1 |
| Takahashi, K | 1 |
| Benaim, EA | 1 |
| Karam, JA | 1 |
| Soboorian, MH | 1 |
| Roehrborn, CG | 1 |
| McConnell, JD | 2 |
| Lin, V | 1 |
| Gao, W | 1 |
| Kearbey, JD | 1 |
| Nair, VA | 1 |
| Chung, K | 1 |
| Parlow, AF | 1 |
| Miller, DD | 1 |
| Dalton, JT | 1 |
| Oliveira, SM | 1 |
| Leite Vilamaior, PS | 1 |
| Corradi, LS | 1 |
| Góes, RM | 1 |
| Taboga, SR | 1 |
| Geller, J | 3 |
| Albert, J | 1 |
| Nachtsheim, DA | 1 |
| Loza, D | 1 |
| Geller, S | 1 |
| Takahashi, S | 1 |
| Hasegawa, F | 1 |
| Isurugi, K | 1 |
| Caine, M | 2 |
| Sionit, LR | 2 |
| Baird, A | 1 |
| Kohls, M | 1 |
| Connors, KM | 1 |
| Hoffman, RM | 2 |
| Montironi, R | 1 |
| Magi-Galluzzi, C | 1 |
| Muzzonigro, G | 1 |
| Prete, E | 1 |
| Polito, M | 1 |
| Fabris, G | 1 |
| el Etreby, MF | 1 |
| Habenicht, UF | 1 |
| Horninger, W | 1 |
| Bartsch, G | 1 |
| Brenner, PC | 1 |
| Rettig, WJ | 1 |
| Sanz-Moncasi, MP | 1 |
| Reuter, V | 1 |
| Aprikian, A | 1 |
| Old, LJ | 1 |
| Fair, WR | 1 |
| Garin-Chesa, P | 1 |
| Tutrone, RF | 1 |
| Ball, RA | 1 |
| Ornitz, DM | 1 |
| Leder, P | 1 |
| Richie, JP | 1 |
| Wysowski, DK | 1 |
| Freiman, JP | 1 |
| Tourtelot, JB | 1 |
| Horton, ML | 1 |
| Marshall, S | 1 |
| Narayan, P | 2 |
| Strohmaier, WL | 1 |
| Flüchter, SH | 1 |
| Wilbert, DM | 1 |
| Bichler, KH | 1 |
| Benassayag, E | 1 |
| Trachtenberg, J | 1 |
| Lepor, H | 2 |
| Debruyne, FM | 1 |
| Tewari, A | 1 |
| Stone, N | 1 |
| Das, S | 1 |
| Jimenez-Cruz, JF | 1 |
| Shearer, R | 1 |
| Klimberg, I | 1 |
| Schellhammer, PF | 1 |
| Costello, AJ | 1 |
| Guate, JL | 1 |
| Escaf, S | 1 |
| Menendez, CL | 1 |
| del Valle, M | 1 |
| Vega, JA | 1 |
| Akakura, K | 1 |
| Furuya, Y | 1 |
| Ito, H | 1 |
| Granados, EA | 1 |
| Zhang, YY | 1 |
| Li, PF | 1 |
| Chen, BL | 1 |
| Li, D | 1 |
| Bonard, M | 1 |
| de Almeida, S | 1 |
| von Niederhäusern, W | 1 |
| Prout, GR | 1 |
| Kliman, B | 1 |
| Daly, JJ | 1 |
| Maclaughlin, RA | 1 |
| Griffin, PP | 1 |
| Neri, RO | 1 |
| Perlberg, S | 1 |
| Gordon, R | 1 |
| Syrkin, AB | 1 |
| Smirnova, IO | 1 |
| Lazarev, NI | 1 |
| Lakey, WH | 1 |
| Bruchovsky, N | 1 |
| Callaway, T | 1 |
| Comeau, T | 1 |
| Lieskovsky, G | 1 |
| Rennie, P | 1 |
| Shnitka, T | 1 |
| Wilkin, P | 1 |
| Romics, I | 1 |
| Bach, D | 1 |
| Connors, K | 1 |
| Levine, AC | 1 |
| Ren, M | 1 |
| Huber, GK | 1 |
| Kirschenbaum, A | 1 |
| Machi, G | 1 |
| Van Cangh, PJ | 1 |
| Petrangeli, E | 1 |
| Sciarra, F | 1 |
| Di Silverio, F | 1 |
| Toscano, V | 1 |
| Lubrano, C | 1 |
| Conti, C | 1 |
| Concolino, G | 1 |
| Namer, M | 1 |
| Neri, R | 1 |
| Stone, NN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Medical Therapy of Prostatic Symptoms[NCT00021814] | Phase 3 | 3,407 participants (Actual) | Interventional | 1995-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for flutamide and Adenoma, Prostatic
| Article | Year |
|---|---|
[Application of antiandrogens on prostatic diseases].
Topics: Androgen Antagonists; Chlormadinone Acetate; Clinical Trials as Topic; Flutamide; Humans; Male; Pros | 1994 |
[Terazosine in the treatment of benign prostatic hypertrophy].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Drug Therapy, Combination; Flutamide; Humans; Ma | 1993 |
The function and the role of aromatase inhibitors in the treatment of BPH.
Topics: Androgens; Androstenedione; Animals; Aromatase Inhibitors; Clinical Trials as Topic; Disease Models, | 1994 |
[Hormonal therapy of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Androgen Antagonists; Clinical Trials as Topic; Cyprotero | 1995 |
[Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Topics: Androgen Antagonists; Anilides; Chlormadinone Acetate; Flutamide; Humans; Male; Neoplasms, Hormone-D | 1998 |
Antiandrogens.
Topics: Acne Vulgaris; Androgen Antagonists; Animals; Biological Assay; Comb and Wattles; Cyproterone; Femal | 1976 |
Androgen ablation and blockade in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstenes; Azasteroids; Finasteride; Flutamide | 1990 |
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; | 1988 |
Pharmacology and pharmacokinetics of flutamide.
Topics: Anilides; Animals; Flutamide; Male; Prostate; Prostatic Hyperplasia; Seminal Vesicles | 1989 |
8 trials available for flutamide and Adenoma, Prostatic
| Article | Year |
|---|---|
The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Mi | 2004 |
[Indications of antiandrogens in benign hyperplasia of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Imidazoles; I | 1995 |
A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.
Topics: Aged; Androgen Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Flutamide; Humans | 1996 |
Placebo-controlled double-blind study in human benign obstructive prostatic hypertrophy with flutamide.
Topics: Anilides; Clinical Trials as Topic; Flutamide; Humans; Male; Middle Aged; Organ Size; Placebos; Pros | 1976 |
The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study.
Topics: Anilides; Biopsy, Needle; Clinical Trials as Topic; Flutamide; Gynecomastia; Humans; Male; Placebos; | 1975 |
[The anti-androgen flutamide in the treatment of prostatic hyperplasia].
Topics: Androgen Antagonists; Dose-Response Relationship, Drug; Flutamide; Humans; Male; Prostatic Hyperplas | 1992 |
Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia.
Topics: Androgen Antagonists; Anilides; Cell Nucleus; Cyproterone; Cyproterone Acetate; Cytosol; Dihydrotest | 1988 |
Flutamide in treatment of benign prostatic hypertrophy.
Topics: Anilides; Double-Blind Method; Flutamide; Humans; Male; Multicenter Studies as Topic; Prostatic Hype | 1989 |
24 other studies available for flutamide and Adenoma, Prostatic
| Article | Year |
|---|---|
Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Blood-Brain Barrier; Drug Design; Drug Screeni | 2011 |
Androgens regulate adenylate cyclase activity and intracellular calcium in stromal cells derived from human prostate.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Aged; Androgen Antagonists; Androgens; Calcium; Cycl | 2010 |
Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Diseases, Metabolic; Finasteride; | 2012 |
Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Orchie | 2004 |
Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgens | 2004 |
Cellular and extracellular behavior in the gerbil (Meriones unguiculatus) ventral prostate following different types of castration and the consequences of testosterone replacement.
Topics: Acid Phosphatase; Androgen Antagonists; Animals; Cyproterone; Disease Models, Animal; Endoplasmic Re | 2007 |
The effects of flutamide on total DHT and nuclear DHT levels in the human prostate.
Topics: Acid Phosphatase; Administration, Oral; Anilides; Cell Nucleus; Dihydrotestosterone; Flutamide; Huma | 1981 |
In vivo and in vitro effects of androgen on fibroblast growth factor-2 concentrations in the human prostate.
Topics: Androgen Antagonists; Cell Division; Culture Techniques; Dihydrotestosterone; Fibroblast Growth Fact | 1994 |
Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma in Situ; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasin | 1994 |
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antigens, Neoplasm; Bone Neoplasms; Flutamide; Glycoproteins | 1995 |
Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model.
Topics: 5-alpha Reductase Inhibitors; Androstenes; Animals; Azasteroids; Dihydrotestosterone; Disease Models | 1993 |
Fatal and nonfatal hepatotoxicity associated with flutamide.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemothera | 1993 |
Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation.
Topics: Aged; Aged, 80 and over; Diethylstilbestrol; Estrogens, Conjugated (USP); Flutamide; Hematuria; Huma | 1993 |
Influence of transrectal hyperthermia on prostate-specific antigen in prostatic cancer and benign prostatic hyperplasia.
Topics: Aged; Combined Modality Therapy; Epirubicin; Flutamide; Humans; Hyperthermia, Induced; Male; Prostat | 1993 |
Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; | 1997 |
[Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery].
Topics: Androgen Antagonists; Flutamide; Humans; Male; Middle Aged; Prostatic Hyperplasia | 1998 |
Flutamide suppressed prostate hypertrophy in rats and mice.
Topics: Androgen Antagonists; Animals; Dose-Response Relationship, Drug; Estradiol; Flutamide; Male; Mice; O | 1999 |
In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.
Topics: Aged; Culture Techniques; Diethylstilbestrol; Dihydrotestosterone; Flutamide; Humans; Lymphatic Meta | 1976 |
The treatment of hypertrophy of the prostate of rats with 4-nitro-3-trifluoromethylisobutyranilide (Sch 13521).
Topics: Anilides; Animals; Behavior, Animal; Castration; Flutamide; Male; Organ Size; Prostate; Prostatic Hy | 1977 |
Androgen receptors in benign and malignant prostatic tissue.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgen Antagonists; Animals; Cyproterone; Dihydrotestostero | 1979 |
Measurement of androgen sensitivity in the human prostate in in vitro three-dimensional histoculture.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Dihydrotestosterone; Flutamide; Histological Te | 1992 |
The effect of androgen, estrogen, and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates.
Topics: Cell Division; Cells, Cultured; Dihydrotestosterone; Epidermal Growth Factor; Estradiol; Female; Fet | 1992 |
The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged; | 1992 |
[Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
Topics: Androgen Antagonists; Aromatase Inhibitors; Cholestenone 5 alpha-Reductase; Cyproterone Acetate; Enz | 1992 |